Own immune cells may repair kidneys in diabetes trial
NCT ID NCT06866158
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 26 times
Summary
This early-phase trial tests whether a single injection of a patient's own immune cells (dendritic cells and lymphocytes) can reduce protein leakage in the urine, a sign of kidney damage, in 80 adults with type 2 diabetes and diabetic kidney disease. The treatment aims to calm inflammation and repair blood vessels. Participants receive one injection and are monitored for four weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE (DKD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gatot Soebroto Central Army Hospital
Jakarta Pusat, DKI Jakarta - Jakarta, 10410, Indonesia
Conditions
Explore the condition pages connected to this study.